EvolveImmune Therapeutics
Branford
About EvolveImmune Therapeutics
EvolveImmune is pioneering a pipeline of unique trispecific T cell engagers with integrated CD2 costimulation. The EVOLVE platform tackles the treatment challenges of cancer cell resistance to current immunotherapies. The company’s lead internal drug candidate, EVOLVE104, will enter the clinic in 2025. EvolveImmune has also partnered with Abbvie to develop additional therapeutics that leverage the power of costimulation.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $74.9M
- Last round: Series Unknown (Oct 2024)
- Website: evolveimmune.com
- Phone: (203) 208-6584
Industries & Categories
Biotechnology, Health Care, Medical, Oncology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/evolveimmune-therapeutics-18287 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.